Beam Therapeutics Inc (BEAM)
$22.24
0.29 (1.29%)
BEAM Stock Quote Delayed 30 Minutes
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.76B
PE Ratio
-20.59
EPS
-1.08
Volume (Avg. Vol.)
1.02M
Day's Range
$21.63 - $22.27
52-Week Range
$16.95 - $49.50
Dividend & Yield
N/A (N/A)
BEAM Stock Predictions, Articles, and Beam Therapeutics Inc News
7 ‘Next Big Things’ for Investors to Buy for 2023
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News
Beam Therapeutics (BEAM) stock is slipping on Monday after the U.S. Food and Drug Administration placed a clinical hold on one of its drugs.
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Investing in CRISPR Stocks: Ultimate Genetic Editing Guide
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy.
